JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from $48 to $33.
November 11, 12:03 PM
The European Commission has approved Agios Pharmaceuticals Inc’s (NASDAQ:AGIO) Pyrukynd (mitapivat) for PK deficiency in adult patients. Pyrukynd is a first-in-class,…
September 1, 12:47 PM
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 94.4% to $27.24. ShiftPixy announced a 1-for-100 reverse stock split.
August 5, 12:36 PM
SVB Leerink analyst Andrew Berens maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and raises the price target from $33 to $37.